Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin

Spotlight on the clinical value of enfortumab vedotin in la/mUC: A review of the EV-301 core data

Date

03 Dec 2022

Session

Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin

Topics

Tumour Site

Urothelial Cancer

Presenters

Thomas Powles

Authors

T.B. Powles

Author affiliations

  • Oncology Department, St. Bartholomew's Hospital - Barts Health NHS Trust, EC1A 7BE - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Welcome and introduction

Presenter: Alvin Wong

Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin

Resources:

Webcast

Panel discussion / Q&A

Presenter: Alvin Wong

Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.